Kite Pharma to Present at IBC Life Sciences' IMMUNO-ONCOLOGY: Advancing the Next Generation of Cancer Immunotherapies Conference

SANTA MONICA, Calif.Sept. 24, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today announced that Marc Better Ph.D., Vice President, Product Sciences, will present during the opening plenary session at IBC Life Sciences' IMMUNO-ONCOLOGY: Advancing the Next Generation of Cancer Immunotherapies Conference, taking place in Alexandria, VASeptember 30 - October 1, 2015. Dr. Better's presentation, "Overcoming Challenges for Engineered Autologous T Cell Therapy," will take place on Wednesday, September 30, 2015, at 8:15am Eastern Time. In addition, a podcast and article related to Dr. Better's participation in the upcoming event are available via the Calendar of Events section of Kite's website at ir.kitepharma.com.

About Kite Pharma, Inc.

Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous cell therapy (eACTâ„¢) designed to restore the immune system's ability to recognize and eradicate tumors. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com.

CONTACT: Kite Pharma



         Cynthia M. Butitta

         Chief Financial Officer and Chief Operating Officer

         310-824-9999



         For Media: Justin Jackson

         For Investor Inquiries: Lisa Burns

         Burns McClellan

         212-213-0006

         jjackson@burnsmc.com

         lburns@burnsmc.com

Source: Kite Pharma, Inc.

News Provided by Acquire Media